ANVISA guidelines for two-stage design [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2020-02-12 09:27 (1526 d 06:29 ago) – Posting: # 21162
Views: 6,314

Hi MS,

Art.75. For two-stage studies, the following should be noted: It is acceptable to use a two-stage approach to demonstrate bioequivalence based on ignorance of the intra-individual variability of the drug;



Ermmm...... WHAT???? :-D:party:

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
22,985 posts in 4,823 threads, 1,653 registered users;
46 visitors (0 registered, 46 guests [including 12 identified bots]).
Forum time: 16:56 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5